An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: April 22, 2005
Last updated: September 8, 2015
Last verified: September 2015
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).

Condition Intervention Phase
Drug: MK0364
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients

Further study details as provided by Merck Sharp & Dohme Corp.:

Enrollment: 500
Study Start Date: July 2004
Study Completion Date: February 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who are obese (considerably overweight) based on body mass index.

Exclusion Criteria:

  • Patients with serious or unstable current or past medical conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00109148

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00109148     History of Changes
Other Study ID Numbers: 0364-006  2005_011 
Study First Received: April 22, 2005
Last Updated: September 8, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Obesity and obesity-related medical conditions processed this record on May 26, 2016